reference/36648229

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/36648229

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Multicenter Study\|Journal Article
issn	1664-3224
pageRange	1298418-
publicationName	Frontiers in Immunology
startingPage	1298418
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_8a5d849afec6e903df0709f61258052c
bibliographicCitation	Mo Y, Pan Y, Zhang B, Zhang J, Su Y, Liu Z, Luo M, Qin G, Kong X, Zhang R, Pan Y, Liang Y, Wang D, Wei Y, Chen H, Jiang W. Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study. Front Immunol. 2023;14():1298418. PMID: 38239359; PMCID: PMC10795162.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_51012de70d882b823cc5058eb13ce7ee http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b2ba384eb34145c038840ff4b028bfda http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2828ac78b45e374a0322cce149ea6861 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7ce593fc814197171f249bdb519af9cc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f250dbc29e2fb6120c4d653bf9ee6153 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c07676ccfc75dd4eea52a411d281c9a5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d9a0443e907d4ebb556dcbce76c8b36c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6b34e374ab06123b21d451794b485029 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_95414a47d928e2c42043adb245a2548b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3c31ded1dc1148f6e684735d21a032d5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_741734cd7dc29bb1028a5f74caeee1c9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a76890bcc7607a13621f4efbb813572f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0d7e636bb1f491db3c84fa1f1babc6f6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4a894942bd3d3b623145c50d5d353bd5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f404b698485e56b1fd24ed65d0db2339 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6c2ca57ac8ae042ec4bb2b5b743a7457
date	2024-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.3389/fimmu.2023.1298418 https://pubmed.ncbi.nlm.nih.gov/PMC10795162 https://pubmed.ncbi.nlm.nih.gov/38239359
isPartOf	https://portal.issn.org/resource/ISSN/1664-3224 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/39309
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study
discusses	http://id.nlm.nih.gov/mesh/M000651317 http://id.nlm.nih.gov/mesh/M0551682 http://id.nlm.nih.gov/mesh/M0018233 http://id.nlm.nih.gov/mesh/M0556300
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D061067 http://id.nlm.nih.gov/mesh/D009303Q000188 http://id.nlm.nih.gov/mesh/D011725
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D000077274Q000188 http://id.nlm.nih.gov/mesh/D011446 http://id.nlm.nih.gov/mesh/D006801

Total number of triples: 43.